Drug Trial Radar · NCT03766997
Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)
Last checked: Nov 20, 2026Latest source record: Dec 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 19, 2019
Primary completion
Jan 2021
Study completion Jan 2022
Sponsor
- Lead sponsor
- Peking Union Medical College HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the clinical response rate of local steroids in the treatment of idiopathic granulomatous mastitis in female adults. Half of the participants will receive local injection combined with topical steroids and the other half will receive topical steroids mono-therapy.
Conditions
- Granulomatous Mastitis
Interventions
Compound Betamethasone InjectionDrug
local injection
Hydrocortisone Butyrate 0.1% CreamDrug
topical use
Primary outcomes
What the sponsor says the trial is designed to measure.
- clinical response rateTime frame: six months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Breast Surgery,Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.